[1]
|
Bailes, J. and Soloviev, M. (2021) Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports. Biomolecules, 11, Article 217. https://doi.org/10.3390/biom11020217
|
[2]
|
Adamo, M.L., Neu-enschwander, S., LeRoith, D., et al. (1993) Structure, Expression, and Regulation of the IGF-I Gene. In: Le Roith, D. and Raizada, M.K., Eds., Current Directions in Insulin-Like Growth Factor Research, Springer, Boston, 1-11. https://doi.org/10.1007/978-1-4615-2988-0_1
|
[3]
|
LeRoith, D., Holly, J.M.P. and Forbes, B.E. (2021) Insu-lin-Like Growth Factors: Ligands, Binding Proteins, and Receptors. Molecular Metabolism, 52, Article ID: 101245. https://doi.org/10.1016/j.molmet.2021.101245
|
[4]
|
Tidblad, A. (2022) The History, Physiology and Treatment Safety of Growth Hormone. Acta Paediatrica, 111, 215-224.
https://doi.org/10.1111/apa.15948
|
[5]
|
Giustina, A. and Veldhuis, J.D. (1998) Pathophysiology of the Neuroregu-lation of Growth Hormone Secretion in Experimental Animals and the Human. Endocrine Reviews, 19, 717-797. https://doi.org/10.1210/edrv.19.6.0353
|
[6]
|
Brabant, G. and Wallaschofski, H. (2007) Normal Levels of Serum IGF-I: Determinants and Validity of Current Reference Ranges. Pituitary, 10, 129-133. https://doi.org/10.1007/s11102-007-0035-9
|
[7]
|
中国垂体腺瘤协作组. 中国肢端肥大症诊治共识(2021版) [J]. 中华医学杂志, 2021, 101(27): 2115-2126.
|
[8]
|
Brooke, A.M. and Drake, W.M. (2007) Serum IGF-I Levels in the Diagnosis and Monitoring of Acromegaly. Pituitary, 10, 173-179. https://doi.org/10.1007/s11102-007-0036-8
|
[9]
|
Giustina, A., Barkhoudarian, G., Beckers, A., et al. (2020) Multi-disciplinary Management of Acromegaly: A Consensus. Reviews in Endocrine and Metabolic Disorders, 21, 667-678. https://doi.org/10.1007/s11154-020-09588-z
|
[10]
|
Oldfield, E.H., Jane, J.A., Thorner, M.O., et al. (2017) Correla-tion between GH and IGF-1 during Treatment for Acromegaly. Journal of Neurosurgery, 126, 1959-1966. https://doi.org/10.3171/2016.8.JNS161123
|
[11]
|
Du, F., Chen, Q., Wang, X., et al. (2021) Long-Term Facial Changes and Clinical Correlations in Patients with Treated Acromegaly: A Cohort Study. European Journal of Endocri-nology, 184, 231-241.
https://doi.org/10.1530/EJE-20-0962
|
[12]
|
Babu, H., Ortega, A., Nuno, M., et al. (2017) Long-Term Endocrine Outcomes following Endoscopic Endonasal Transsphenoidal Surgery for Acromegaly and Associated Prognostic Factors. Neurosurgery, 81, 357-366.
https://doi.org/10.1093/neuros/nyx020
|
[13]
|
McCabe, J., Ayuk, J. and Sherlock, M. (2016) Treatment Factors That Influence Mortality in Acromegaly. Neuroendocrinology, 103, 66-74. https://doi.org/10.1159/000375163
|
[14]
|
Thomas, M., Berni, E., Jenkins Jones, S., et al. (2021) Insulin-Like Growth Factor-1, Growth Hormone and Disease Outcomes in Acromegaly: A Population Study. Clinical Endocrinology, 95, 143-152.
https://doi.org/10.1111/cen.14468
|
[15]
|
Holdaway, I.M., Rajasoorya, R.C. and Gamble, G.D. (2004) Factors Influ-encing Mortality in Acromegaly. The Journal of Clinical Endocrinology & Metabolism, 89, 667-674. https://doi.org/10.1210/jc.2003-031199
|
[16]
|
Melmed, S. (2019) Pathogenesis and Diagnosis of Growth Hormone Deficiency in Adults. The New England Journal of Medicine, 380, 2551-2562. https://doi.org/10.1056/NEJMra1817346
|
[17]
|
Shen, Y., Zhang, J., Zhao, Y., et al. (2015) Diagnostic Value of Se-rum IGF-1 and IGFBP-3 in Growth Hormone Deficiency: A Systematic Review with Meta-Analysis. European Journal of Pediatrics, 174, 419-427.
https://doi.org/10.1007/s00431-014-2406-3
|
[18]
|
Bowers, L.W., Rossi, E.L., Oâ Flanagan, C.H., et al. (2015) The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link. Frontiers in Endocrinology, 6, Article 77.
https://doi.org/10.3389/fendo.2015.00077
|
[19]
|
Matsushita, M., Fujita, K., Hatano, K., et al. (2022) Connecting the Dots between the Gut—IGF-1—Prostate Axis: A Role of IGF-1 in Prostate Carcinogenesis. Frontiers in Endocrinology, 13, Article 852382.
https://doi.org/10.3389/fendo.2022.852382
|
[20]
|
Cao, Y., Nimptsch, K., Shui, I.M., et al. (2015) Prediagnostic Plasma IGFBP-1, IGF-1 and Risk of Prostate Cancer. International Journal of Cancer, 136, 2418-2426. https://doi.org/10.1002/ijc.29295
|
[21]
|
González-Zuloeta Ladd, A.M., Liu, F., Houben, M.P.W.A., et al. (2007) IGF-1 CA Repeat Variant and Breast Cancer Risk in Postmenopausal Women. European Journal of Cancer, 43, 1718-1722.
https://doi.org/10.1016/j.ejca.2007.04.026
|
[22]
|
Hang, D., He, X., Kværner, A.S., et al. (2019) Plasma Biomarkers of Insulin and the Insulin-Like Growth Factor Axis, and Risk of Colorectal Adenoma and Serrated Polyp. JNCI Cancer Spectrum, 3, pkz56.
https://doi.org/10.1093/jncics/pkz056
|
[23]
|
Han, L., Zhang, G.F., Cheng, Y.H., et al. (2016) Correlations of Insu-lin-Like Growth Factor I and Insulin-Like Growth Factor I Receptor with the Clinicopathological Features and Prognosis of Patients with Colon Cancer. Japanese Journal of Clinical Oncology, 46, 1-8. https://doi.org/10.1093/jjco/hyw137
|
[24]
|
M’Hamdi, H., Baizig, N.M., El Hadj, O.E., et al. (2016) Usefulness of IGF-1 Serum Levels as Diagnostic Marker of Nasopharyngeal Carcinoma. Immunobiology, 221, 1304-1308. https://doi.org/10.1016/j.imbio.2016.05.008
|
[25]
|
Juul, A., Scheike, T., Davidsen, M., et al. (2002) Low Serum In-sulin-Like Growth Factor I Is Associated with Increased Risk of Ischemic Heart Disease: A Population-Based Case-Control Study. Circulation, 106, 939-944.
https://doi.org/10.1161/01.CIR.0000027563.44593.CC
|
[26]
|
Hinojosa-Amaya, J.M., Varlamov, E.V., Yedinak, C.G., et al. (2021) Echocardiographic Findings in Acromegaly: Prevalence of Concentric Left Ventricular Remodeling in a Large Single-Center Cohort. Journal of Endocrinological Investigation, 44, 2665-2674. https://doi.org/10.1007/s40618-021-01579-4
|
[27]
|
Ruidavets, J.B., Luc, G., Machez, E., et al. (2011) Effects of In-sulin-Like Growth Factor 1 in Preventing Acute Coronary Syndromes: The PRIME Study. Atherosclerosis, 218, 464-469.
https://doi.org/10.1016/j.atherosclerosis.2011.05.034
|
[28]
|
De Lorenzo, A., Moreira, A.S.B., Souza, E.G., et al. (2016) Insulin-Like Growth Factor-1 in Early-Onset Coronary Artery Disease: Insights into the Pathophysiology of Atherosclerosis. International Journal of Cardiology, 202, 1-2.
https://doi.org/10.1016/j.ijcard.2015.04.032
|
[29]
|
Johnsen, S.P., Hundborg, H.H., Sørensen, H.T., et al. (2005) In-sulin-Like Growth Factor (IGF) I, -II, and IGF Binding Protein-3 and Risk of Ischemic Stroke. The Journal of Clinical Endocrinology & Metabolism, 90, 5937-5941.
https://doi.org/10.1210/jc.2004-2088
|
[30]
|
Kaplan, R.C., McGinn, A.P., Pollak, M.N., et al. (2007) Association of Total Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein-1 (IGFBP-1), and IGFBP-3 Levels with Incident Coronary Events and Ischemic Stroke. The Journal of Clinical Endocrinology & Metabolism, 92, 1319-1325. https://doi.org/10.1210/jc.2006-1631
|
[31]
|
Saber, H., Himali, J.J., Beiser, A.S., et al. (2017) Serum In-sulin-Like Growth Factor 1 and the Risk of Ischemic Stroke. Stroke, 48, 1760-1765. https://doi.org/10.1161/STROKEAHA.116.016563
|